medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2022, Number 6

<< Back Next >>

Acta Pediatr Mex 2022; 43 (6)

COVID-19 in the context of inborn errors of immunity, autoimmune diseases, and immune suppression

Lugo-Reyes SO, Medina-Torres EA, Espinosa-Padilla SE

Language: Spanish
References: 29
Page: 358-365
PDF size: 232.30 Kb.


ABSTRACT

The COVID-19 pandemic reached five waves in three years, with over 6.5 million deaths across the globe. Knowing the differential susceptibility to the novel betacoronavirus has allowed us to better understand the pathophysiology and inflammatory complications and dissect the response against the virus. As in other viral infections, CD8+ T lymphocytes and NK cells stand out as key players, together with viral sensors, type 1 interferons, an exaggerated inflammatory response by NLRP3, and a storm that includes cytokines IL-6 and IL-8. Whole-exome sequencing has identified several genes with pathogenic germline variants in patients with severe COVID-19; said genes would account for around 5% of all severe cases. In addition, up to 20% of hospitalized adults harbor autoantibodies against type-I and III interferons. These findings translate into novel genetic etiologies, whereas autoantibodies explain the worse prognosis of the elderly, linked to the inflammaging phenomenon. In general, patients with known primary immune deficiencies who acquired COVID-19 fared well, with global survival rates over 80% and a predominance of mild courses. The exceptions were patients with severe-combined immune deficiency, and with the autoimmune polyglandular syndrome 1, the latter because they develop autoantibodies against interferon. Neither have there been reports of greater severity in patients with autoimmune or autoinflammatory disorders. However, those receiving immunosuppressant treatments usually have a more protracted course. Patients with NLRP3 or STAT1 gain of function might be especially susceptible to systemic inflammatory complications. In this review, we summarize the global experience in the caretaking of patients with immune alterations who were infected by SARS-CoV-2.


REFERENCES

  1. COVID-19 Map - Johns Hopkins Coronavirus ResourceCenter. https://coronavirus.jhu.edu/map.html. AccessedFebruary 10, 2021.

  2. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human Inborn Errors of Immunity:2019 Update on the Classification from the InternationalUnion of Immunological Societies Expert Committee. JClin Immunol. 2020;40(1):24-64. doi:10.1007/s10875-019-00737-x

  3. Berman JJ. Rare Diseases and Orphan Drugs. First Edit. SanDiego, CA, USA: Elsevier; 2014.

  4. Gupta S, Su H, Narsai T, Agrawal S. SARS-CoV-2-AssociatedT-Cell Responses in the Presence of Humoral Immunodeficiency.Exp Immunol Artic Int Arch Allergy Immunol. 2021.doi:10.1159/000514193

  5. Wang J, Li Q, Yin Y, Zhang Y, Cao Y, Lin X, et al. ExcessiveNeutrophils and Neutrophil Extracellular Traps inCOVID-19. Front Immunol. 2020;11:2063. doi:10.3389/fimmu.2020.02063

  6. Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J, et al. PotentialInfluence of Menstrual Status and Sex Hormones on FemaleSevere Acute Respiratory Syndrome Coronavirus 2 Infection:A Cross-sectional Multicenter Study in Wuhan, China.Clin Infect Dis. 2020; 371: 6527. doi:10.1093/cid/ciaa1022

  7. Simonnet A, Chetboun M, Poissy J, Raverdy V, NouletteJ, Duhamel A, et al. High Prevalence of Obesity in SevereAcute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Requiring Invasive Mechanical Ventilation. Obesity.2020;28(7):1195-1199. doi:10.1002/oby.22831

  8. Peron JPS, Nakaya H. Susceptibility of the Elderly to SARSCoV-2 Infection: ACE-2 Overexpression, Shedding, andAntibody-dependent Enhancement (ADE). Clinics (SaoPaulo). 2020;75:e1912. doi:10.6061/clinics/2020/e1912

  9. Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D,Polverino F, et al. Type 2 Inflammation Modulates ACE2 andTMPRSS2 in Airway Epithelial Cells. J Allergy Clin Immunol.2020 Jul;146(1):80-88.e8. doi:10.1016/j.jaci.2020.05.004

  10. Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G,Urban ML, et al. SARS-CoV-2 infection among patientswith systemic autoimmune diseases. Autoimmun Rev.2020;19(7):102575. doi:10.1016/j.autrev.2020.102575

  11. Van Der Made CI, Simons A, Schuurs-Hoeijmakers J, van denHeuvel G, Mantere T, Kersten S, et al. Presence of GeneticVariants among Young Men with Severe COVID-19. JAMA- J Am Med Assoc. 2020;324(7):663-673. doi:10.1001/jama.2020.13719

  12. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, ChenJ, et al. Inborn errors of type I IFN immunity in patientswith life-threatening COVID-19. Science 2020; 370(6515).doi:10.1126/science.abd4570

  13. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q,Manry J, et al. Autoantibodies neutralizing type I IFNs arepresent in ~ 4% of uninfected individuals over 70 yearsand account for ~ 20% of COVID-19 deaths. Sci Immunol.2021;6(62). doi:10.1126/SCIIMMUNOL.ABL4340

  14. Yoni Maisel (@Primary_Immune) / Twitter. https://twitter.com/Primary_Immune. Accessed July 7, 2022.

  15. Bucciol G, Tangye SG, Meyts I. Coronavirus disease 2019in patients with inborn errors of immunity: lessons learned.Curr Opin Pediatr. 2021;33(6):648. doi:10.1097/MOP.0000000000001062

  16. Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, FarkashM, et al. Minor Clinical Impact of COVID-19 Pandemic onPatients With Primary Immunodeficiency in Israel. FrontImmunol. 2021;11:3505. doi:10.3389/fimmu.2020.614086

  17. Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, MezzaromaI, et al. A possible role for B cells in COVID-19?Lesson from patients with agammaglobulinemia. J AllergyClin Immunol. 2020;146(1):211-213.e4. doi:10.1016/j.jaci.2020.04.013

  18. Castano‐Jaramillo LM, Yamazaki‐Nakashimada MA, SchefflerMendoza SC, Bustamante‐Ogando JC, Espinosa‐PadillaSE, Lugo Reyes SO. A male infant with COVID‐19 in the contextof ARPC1B deficiency. Eigenmann P, ed. Pediatr AllergyImmunol. 2021;32(1):199-201. doi:10.1111/pai.13322

  19. Pereira MFB, Litvinov N, Farhat SCL, Eisencraft AP, GibelliMABC, Carvalho WB, et al. Severe clinical spectrum withhigh mortality in pediatric patients with covid-19 andmultisystem inflammatory syndrome. Clinics. 2020;75:1-7.doi:10.6061/clinics/2020/e2209

  20. Bastard P, Orlova E, Sozaeva L, Levy R, James A, SchmittMM, et al. Preexisting autoantibodies to type IIFNs underlie critical COVID-19 pneumonia in patientswith APS-1. J Exp Med. 2021;218(7):29. doi:10.1084/JEM.20210554/212019

  21. London J, Boutboul D, Lacombe K, Pirenne F, Heym B,Zeller V, et al. Severe COVID-19 in Patients with B CellAlymphocytosis and Response to Convalescent PlasmaTherapy. J Clin Immunol. 2020;41(2):356-361. doi:10.1007/s10875-020-00904-5

  22. Pontali E, Volpi S, Signori A, Antonucci G, Castellaneta M,Buzzi D, et al. Efficacy of early anti-inflammatory treatmentwith high doses IV Anakinra with or without glucocorticoidsin patients with severe COVID-19 pneumonia. J AllergyClin Immunol 2021 Apr; 147(4): 1217-1225. doi:10.1016/j.jaci.2021.01.024

  23. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, SeoaneE, et al. Coronavirus disease 2019 in patients with inbornerrors of immunity: An international study. J AllergyClin Immunol. 2020;147(2):520-531. doi:10.1016/j.jaci.2020.09.010

  24. Castano-Jaramillo LM, Yamazaki-Nakashimada MA,O’Farrill-Romanillos PM, Muzquiz Zermeño D, SchefflerMendoza SC, Venegas Montoya E, et al. COVID-19 in theContext of Inborn Errors of Immunity: a Case Series of 31Patients from Mexico. J Clin Immunol. 2021;41(7):1463-1478. doi:10.1007/s10875-021-01077-5

  25. Trump Makes Claim About Lupus and Coronavirus—But‘Maybe It’s False.’ https://www.forbes.com/sites/carlieporterfield/2020/04/04/trump-makes-claim-about-lupusand-coronavirus-but-maybe-its-false/?sh=68e3d3da72d7.Accessed February 10, 2021.

  26. Trump-touted hydroxychloroquine in short supply forlupus patients. https://medicalxpress.com/news/2020-06-trump-touted-hydroxychloroquine-short-lupuspatients.html. Accessed February 10, 2021.

  27. Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-RodriguezL, Font Urgelles J, Madrid García A, et al. Risk factorsfor hospital admissions related to COVID-19 in patientswith autoimmune inflammatory rheumatic diseases. AnnRheum Dis. 2020;79(11):1393-1399. doi:10.1136/annrheumdis-2020-217984

  28. Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH,Fink SL. Prevalence of autoantibody responses in acutecoronavirus disease 2019 (COVID-19). J Transl Autoimmun.2020;3:100073. doi:10.1016/j.jtauto.2020.100073

  29. El Hasbani G, Taher AT, Jawad A, Uthman I. COVID-19,Antiphospholipid Antibodies, and Catastrophic AntiphospholipidSyndrome: A Possible Association? ClinMed Insights Arthritis Musculoskelet Disord. 2020;13.doi:10.1177/1179544120978667




2020     |     www.medigraphic.com